Observational studyAdvances in therapy2019

Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control.

Nikolaos Tentolouris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.